phone icon  Toll Free : +1-800-792-5285 | (UK) : + 44-845-528-1300
Allied Market Research

0
Shopping Cart is Empty..
$ 0
CART  yellow arrow
 

Nanomedicine Market Overview:

Global Nanomedicine Market accounted for $111,912 million in 2016, and is anticipated to reach $261,063 million by 2023, registering a CAGR of 12.6% from 2017 to 2023. Nanomedicine is one of the applications of nanotechnology used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine uses nanoscale manipulation of materials to improve medicine delivery. Thus, nanomedicine has facilitated the treatment against various diseases. Nanomedicine is in nascent stage, as several products are in the development phase. According to Nanobiotix (a nanomedicine company), in 2015, around 230 nanomedicine products were identified, which are either marked or are in the trial phase. Moreover, as per the company, there are 49 nanomedicine products in the market, whereas 122 products are in the clinical pipeline either in Phase II or Phase III trials.

The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. On the basis of indication, it is categorized into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopedic disorders, immunological diseases, cardiovascular diseases, and others. Based on modality, it is bifurcated into treatments and diagnostics. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Global Nanomedicine Market Segmentation

Global Nanomedicine Market Segmentation

 Drivers, Restraints, and Opportunities

The global market is driven by emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support & funding, growth in need for therapies with fewer side effects, and cost-effectiveness of therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are anticipated to provide numerous opportunities for the market growth.

Global Nanomedicine Market: Drivers & Restraints

GLOBAL NANOMEDICINE MARKET: DRIVERS & RESTRAINTS

India Nanomedicine Market

Increase in adoption of novel nanomedicines products drives the market growth in India. Moreover, increase in the number of players and high adoption of innovative technologies further fuel the market growth. In addition, robust government initiative toward improvement of healthcare facilities through insurance schemes is anticipated to provide lucrative growth opportunities in the country. The nanomedicines market in India is expected to grow at the highest CAGR of 13.4% from 2016 to 2023.

India Nanomedicines Market, 2016-2023 ($Million)

INDIA NANOMEDICINES MARKET, 2016-2023 ($MILLION)

The key players operating in the global nanomedicine market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc., Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

The other prominent players in the value chain include Celgene Corporation, UCB (Union Chimique Belge) S.A., AMAG Pharmaceuticals, Nanospectra Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Leadiant Biosciences, Inc., Epeius Biotechnologies Corporation
Gilead, and Cytimmune Sciences, Inc.

Key Benefits

  • The study provides an in-depth analysis of the global nanomedicine market and the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on product assists in understanding the trends in the industry.
  • Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

Nanomedicine Market Key Segments:

By Application

  • Drug Delivery
  • Vaccines
  • Diagnostic Imaging
  • Regenerative Medicine
  • Implants
  • Others

By Modality

  • Diagnostics
  • Treatments

By Indication

  • Oncological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Orthopedic Disorders
  • Neurological Diseases
  • Urological Diseases
  • Ophthalmological Diseases
  • Immunological Diseases
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Argentina
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Title/ Chapter Name

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO

3.4.1. FDA
3.4.2. Health Canada
3.4.3. CE Mark
3.4.4. Ministry of Health, Labor, and Welfare (MHLW)

3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Emerging innovative technologies for drug delivery
3.6.1.2. Increase adoption of nanomedicine across varied applications
3.6.1.3. Rising government support and funding
3.6.1.4. Growing need of therapies that have fewer side effects and are cost effective

3.6.2. Restraints

3.6.2.1. Long approval process
3.6.2.2. Risks associated with nanomedicine (environmental impacts)

3.6.3. Opportunities

3.6.3.1. Growth of healthcare facilities in emerging economies

Chapter: 4 NANOMEDICINE MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. VACCINES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. REGENERATIVE MEDICINE

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. DIAGNOSTIC IMAGING

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. DRUG DELIVERY

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. IMPLANTS

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHERS

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

Chapter: 5 NANOMEDICINE MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ONCOLOGICAL DISEASES

5.2.1. Market size and forecast

5.3. INFECTIOUS DISEASES

5.3.1. Market size and forecast

5.4. CARDIOVASCULAR DISEASES

5.4.1. Market size and forecast

5.5. ORTHOPEDIC DISORDERS

5.5.1. Market size and forecast

5.6. NEUROLOGICAL DISORDERS

5.6.1. Market size and forecast

5.7. UROLOGICAL DISEASES

5.7.1. Market size and forecast

5.8. OPHTHALMOLOGICAL DISEASES

5.8.1. Market size and forecast

5.9. IMMUNOLOGICAL DISEASES

5.9.1. Market size and forecast

5.10. OTHERS

5.10.1. Market size and forecast

Chapter: 6 NANOMEDICINE MARKET, BY MODALITY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. TREATMENTS

6.2.1. Market size and forecast

6.3. DIAGNOSTICS

6.3.1. Market size and forecast

Chapter: 7 NANOMEDICINE MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Mexico market size and forecast
7.2.3.3. Canada market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. UK market size and forecast
7.3.3.3. France market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. India market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Japan market size and forecast
7.4.3.4. Australia market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. South Africa market size and forecast
7.5.3.3. South Arabia market size and forecast
7.5.3.4. Argentina market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments

8.2. COMBIMATRIX CORPORATION

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. GENERAL ELECTRIC COMPANY

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments

8.4. SIGMA-TAU PHARMACEUTICALS, INC.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Key strategic moves and developments

8.5. JOHNSON & JOHNSON PRIVATE LIMITED

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments

8.6. MALLINCKRODT PLC

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments

8.7. MERCK & COMPANY, INC.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments

8.8. LUMINEX CORPORATION

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments

8.9. PFIZER, INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 2. GLOBAL NANOMEDICINE MARKET FOR VACCINES APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL NANOMEDICINE MARKET FOR REGENERATIVE MEDICINE APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTIC IMAGING APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 5. GLOBAL NANOMEDICINE MARKET FOR DRUG DELIVERY APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 6. GLOBAL NANOMEDICINE MARKET FOR IMPLANTS APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL NANOMEDICINE MARKET FOR OTHERS APPLICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL NANOMEDICINE MARKET FOR ONCOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL NANOMEDICINE MARKET FOR INFECTIOUS DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GLOBAL NANOMEDICINE MARKET FOR CARDIOVASCULAR DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GLOBAL NANOMEDICINE MARKET FOR ORTHOPEDIC DIORDERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL NANOMEDICINE MARKET FOR NEUROLOGICAL DISORDERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL NANOMEDICINE MARKET FOR UROLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL NANOMEDICINE MARKET FOR OPHTHALMOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL NANOMEDICINE MARKET FOR IMMUNOLOGICAL DISEASES INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL NANOMEDICINE MARKET FOR OTHERS INDICATION, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 19. GLOBAL NANOMEDICINE MARKET FOR TREATMENT MODALITY, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTICS MODALITY, BY REGION, 2016-2023 ($MILLION)
TABLE 21. NANOMEDICINE MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 26. EUROPE NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. EUROPE NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. EUROPE NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 29. EUROPE NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 30. ASIA-PACIFIC NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 34. LAMEA NANOMEDICINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 35. LAMEA NANOMEDICINE MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. LAMEA NANOMEDICINE MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 37. LAMEA NANOMEDICINE MARKET, BY MODALITY, 2016-2023 ($MILLION)
TABLE 38. ABBOTT: COMPANY SNAPSHOT
TABLE 39. ABBOTT: OPERATING SEGMENTS
TABLE 40. COMBIMATRIX: COMPANY SNAPSHOT
TABLE 41. COMBIMATRIX: OPERATING SEGMENTS
TABLE 42. GE: COMPANY SNAPSHOT
TABLE 43. GE: OPERATING SEGMENTS
TABLE 44. SIGMA: COMPANY SNAPSHOT
TABLE 45. SIGMA: OPERATING SEGMENTS
TABLE 46. J&J: COMPANY SNAPSHOT
TABLE 47. J&J: OPERATING SEGMENTS
TABLE 48. MALLINCKRODT: COMPANY SNAPSHOT
TABLE 49. MALLINCKRODT: OPERATING SEGMENTS
TABLE 50. MERCK: COMPANY SNAPSHOT
TABLE 51. MERCK: OPERATING SEGMENTS
TABLE 52. LUMINEX: COMPANY SNAPSHOT
TABLE 53. LUMINEX: OPERATING SEGMENTS
TABLE 54. PFIZER: COMPANY SNAPSHOT
TABLE 55. PFIZER: OPERATING SEGMENTS
TABLE 56. TEVA: COMPANY SNAPSHOT
TABLE 57. TEVA: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. SNAPSHOT GLOBAL NANOMEDICINE MARKET, 2016-2023
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL NANOMEDICINE MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOTAL NUMBER OF STRATEGIES: GLOBAL DISPOSABLE MEDICAL SENSORS MARKET
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. MARKET SHARE ANALYSIS: NANOMEDICINE MARKET, 2016
FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL NANOMEDICINE MARKET
FIGURE 13. GLOBAL NANOMEDICINE MARKET, BY APPLICATION
FIGURE 14. NANOMEDICINE MARKET, BY INDICATION
FIGURE 15. NANOMEDICINE MARKET, BY REGION
FIGURE 16. NORTH AMERICA NANOMEDICINE MARKET, 2016-2023
FIGURE 17. U.S. NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 18. MEXICO NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 19. CANADA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 20. GERMANY NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 21. UK NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 22. FRANCE NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 23. ITALY NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 24. SPAIN NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 25. REST OF EUROPE NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 26. INDIA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 27. CHINA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 28. JAPAN NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 29. AUSTRALIA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 30. REST OF ASIA-PACIFIC NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 31. BRAZIL NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 32. SOUTH AFRICA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 33. SOUTH ARABIA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 34. ARGENTINA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 35. REST OF LAMEA NANOMEDICINE MARKET, 2016-2023 ($MILLION)
FIGURE 36. ABBOTT: NET SALES, 2014-2017 ($MILLION)
FIGURE 37. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 38. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 39. COMBIMATRIX: NET SALES, 2014-2017 ($MILLION)
FIGURE 40. COMBIMATRIX: REVENUE BY SEGMENT, 2016 (%)
FIGURE 41. COMBIMATRIX: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 42. GE: NET SALES, 2014-2017 ($MILLION)
FIGURE 43. GE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 44. GE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 45. J&J: NET SALES, 2014-2017 ($MILLION)
FIGURE 46. J&J: REVENUE BY SEGMENT, 2016 (%)
FIGURE 47. J&J: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 48. MALLINCKRODT: NET SALES, 2014-2017 ($MILLION)
FIGURE 49. MALLINCKRODT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 50. MALLINCKRODT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 51. MERCK: NET SALES, 2014-2017 ($MILLION)
FIGURE 52. MERCK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 53. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 54. LUMINEX: NET SALES, 2014-2017 ($MILLION)
FIGURE 55. LUMINEX: REVENUE BY SEGMENT, 2016 (%)
FIGURE 56. LUMINEX: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 57. PFIZER: NET SALES, 2014-2017 ($MILLION)
FIGURE 58. PFIZER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 59. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 60. TEVA: NET SALES, 2014-2017 ($MILLION)
FIGURE 61. TEVA: REVENUE BY SEGMENT, 2016 (%)
FIGURE 62. TEVA: REVENUE BY GEOGRAPHY, 2016 (%)

Nanomedicines is an emerging and most promising technology in the 21st century. This is due to the fact that it involves the drug development at molecular scale which helps in easy prevention, diagnosis, treatment, and regeneration of tissues and organs. Thus, these help to preserve and improve human health by offering impressive solutions for several life-threatening diseases such as cancer, Alzheimer’s disease, Parkinson’s disease, diabetes, orthopedic problems, diseases related to blood, neurological, lungs, and cardiovascular system.

The healthcare market has witnessed rapid development in the recent years, thus emerging players have focused on expanding their presence in the nanomedicine sector. Moreover, key players have contributed significantly to the market growth by leveraging product diversification, product commercialization, and product approvals.

DIFFERENT APPROVED PRODUCT OF GLOBAL NANOMEDICINE MARKET

In the diagnosis field, nanomedicine is a cost-effective technique as it requires minimum amount of biological sample, which reduces consumption of disposables and reagents. Moreover, apart from diagnostics, nanomedicine assists in drug delivery by utilizing nanoscale particles with larger surface-to-volume ratio. These particles are allowed to enter into body cavities for the diagnosis or treatment of diseases; thereby, improving the efficacy of treatment and diagnosis and preventing side effects of drugs in case of targeted therapy.

License Type
Data Pack
Single User PDF
Five User Online/PDF
Enterprise Online/PDF
LICENSE INFO
Users/Sharing
Restricted to one authorized user

Restricted to one authorized user

Limited to 5 authorized users


Unlimited within company / enterprise
Printing
One Print only

One Print only
Up to Five Copies
Unlimited within company / enterprise
Delivery Formats
ADDED BENIFITS
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

 
Print Email Facebook Google Plus Twitter LinkedIn Blogger
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to eliminate redundant information to provide valued information and save time of the reader

 

Featured Readings

Further Readings



Sep 2017

Asia Pacific Nanomedicine Market- Opportunities and Forecasts, 2017-2023

 

Get fresh content delivered

Get insights on topics that matter to your business. Stay updated on the areas that interest you.

About
US
Find
HELP
Consulting &
CUSTOM STUDIES
Our
PRODUCTS
Our
SERVICES
Press
MEDIA
STAY WITH US

fb blogger linkedin Gplus twitter Youtube Rss

WE ACCEPT


weAccept